

Special Issue

Headache Disorders: New Advances in Management and Treatment Strategies

Message from the Guest Editors

The recent market release of monoclonal antibodies (MAbs), specifically targeting the calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP MAbs), based on the results of clinical trials and real-life data, appeared as a promising preventative option in both episodic and chronic migraine patients with a much higher efficacy/tolerability ratio, compared to the already available oral and injectable prophylactic treatment of armamentarium. In addition, anti-CGRP MAbs can be used with some degree of success as preventives in other headache disorders

The scope of this Special Issue is to summarize our existing knowledge on the pros and cons of modern therapies for headache disorders, to examine open clinical and pathogenetic issues and to explore future perspectives for future research to pursue. As such, both research papers and reviews are welcome. The Co-Editors and I are confident that it will become a reference point for all those who want to know why, when, and how to treat headache patients with monoclonal antibodies that target the CGRP, gepants or ditans.

Guest Editors

Dr. Andreas A. Argyriou

Neurology Department, Agios Andreas State General Hospital of Patras, 263 35 Patras, Greece

Dr. Vikelis Michail

Headache Clinic, Mediterraneo Hospital, 166 75 Glyfada, Greece

Dr. Emmanouil V. Dermitzakis

Euromedica General Clinic, 546 45 Thessaloniki, Greece

Deadline for manuscript submissions

closed (31 January 2025)



Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/166391

Journal of Clinical Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jcm@mdpi.com

mdpi.com/journal/

jcm





Journal of Clinical Medicine

an Open Access Journal
by MDPI

Impact Factor 2.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/journal/

[jcm](https://mdpi.com/journal/jcm)



About the Journal

Message from the Editorial Board

There has been an explosion of gene and target based research and therapeutics in the multitude of fields that compose clinical medicine. The *Journal of Clinical Medicine's* (JCM) staff and editorial board are dedicated to providing cutting edge, timely, and peer-reviewed articles covering the diverse subspecialties of clinical medicine. The journal publishes concise, innovative, and exciting research articles as well as clinically significant articles and reviews that are pertinent to the myriad of disciplines within medicine. The articles published are relevant to both primary care physicians and specialists. The journal's full-texts are archived in PubMed Central and indexed in PubMed. Please consider submitting your manuscripts for publication to our journal and check us out on-line!

Editors-in-Chief

Prof. Dr. Emmanuel Andrès

Internal Medicine Department, University Hospital Strasbourg, 67081
Strasbourg, France

Prof. Dr. Kent Doi

Department of Emergency and Critical Care Medicine, The University of
Tokyo, Tokyo, Japan

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q1 (General Medicine)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.5 days after submission; acceptance to publication is undertaken in 2.7 days (median values for papers published in this journal in the second half of 2025).